HARVARD BIOSCIENCE INC
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
HBIO$9.26+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| HARVARD BIOSCIENCE, INC. | ||
|---|---|---|
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | ||
| (In thousands) | ||
| Year Ended December 31, | ||
| 2023 | 2022 | |
| Net loss | $(3,415) | $(9,516) |
| Other comprehensive income (loss): | ||
| Foreign currency translation adjustments | 1,507 | (2,614) |
| Defined benefit pension plans, net of tax benefit of $137 and $566, respectively | (446) | (2,411) |
| Derivative instruments qualifying as cash flow hedges, net of tax of $-0- | (199) | - |
| Other comprehensive income (loss) | 862 | (5,025) |
| Comprehensive loss | $(2,553) | $(14,541) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.